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ABSTRACT

Arrhythmias are often caused by aberrant ion channel activity, resulting in
remodeling of the cardiac action potential. Two K+ currents, IKs and IKr, contribute
to phase III repolarization of the human cardiac action potential. Human ether-ago-go-related gene 1 (hERG1), a voltage-gated potassium channel, underlies IKr.
Alterations in the repolarization phase of the action potential, and in particular IKr,
can lead to arrhythmias, long or short QT syndrome, heart disease, and sudden
cardiac death. HERG1A has two putative N-glycosylation sites located in the S5S6 linker region, one of which is N-glycosylated. The aim of the first study was to
determine whether and how N-linked glycosylation modifies hERG1A channel
function. Voltage-dependent gating and kinetics of hERG1A were evaluated
under conditions of full glycosylation, no sialylation, in the absence of complex Nglycans, and following the removal of the full N-glycosylation structure. The
hERG1A steady state activation relationship was shifted linearly along the
voltage axis by a depolarizing ~9 mV under each condition of reduced
glycosylation. Steady state channel availability curves were shifted by a much
greater depolarizing 20–30 mV under conditions of reduced glycosylation. There
was no significant difference in steady state gating parameters among the less
glycosylated channels, suggesting that channel sialic acids are responsible for
viii

most of the effect of N-glycans on hERG1A gating. A large rightward shift in
hERG1A window current for the less glycosylated channels was caused by the
observed depolarizing shifts in steady state activation and inactivation. The
much larger shift in inactivation compared to activation leads to an increase in
hERG1A window current. Together, these data suggest that there is an increase
in the persistent hERG current that occurs at more depolarized potentials under
conditions of reduced glycosylation. This would lead to increased hERG1A
activity during the AP, effectively increasing the rate of repolarization, and
reducing AP duration, as observed through in silico modeling of the ventricular
AP. The data describe a novel mechanism by which hERG1A activity is
modulated by physiological and pathological changes in hERG1A glycosylation,
with increased channel sialylation causing a loss of hERG1A activity that would
likely cause an extension of the ventricular AP. The second study was to
evaluate possible changes in antibiotic drug block as a result of alterations to Nglycosylation. We determined that N-glycans play a protective role on the
hERG1A channel. SMX, Erythromycin, and Penicillin G were assessed
individually at three concentrations. The data showed increases in antibiotic
block with decreases in N-glycans. In addition, alterations in the voltagedependence of block with changes in N-glycans were observed. SMX block was
voltage-independent at each drug concentration under conditions of reduced
sialylation only. Overall, these data indicate a functional role for N-glycosylation
in the modulation of hERG1A antibiotic block, suggesting that even small
changes in channel N-glycosylation modulate hERG1A block, and thereby likely
ix

impact the rate of action potential repolarization. The data from these studies
enhances our understanding of the role of N-glycosylation on hERG1A function
and drug block, and how that role will impact the cardiac action potential and
overall cardiac excitability.

x

CHAPTER 1
INTRODUCTION
Normal heart function
The heart is a muscular organ that is responsible for pumping blood throughout
the body by repeated, rhythmic contractions. It is made up of cardiac muscle
which is found only within this organ. The average human heart beats about 72
times per minute. The right side of the heart collects the de-oxygenated blood
from the body into the right atrium and then pumps it via the right ventricle into
the lungs for gas exchange. Then the left atrium fills with oxygenated blood
before moving to the left ventricle which pumps it out to the body. The ventricles
are thicker and stronger than the atria. The muscle wall surrounding the left
ventricle is thicker than the wall surrounding the right ventricle due to the force
needed to pump the blood through the body.

The heart is effectively a syncytium, a meshwork of cardiac muscle cells
interconnected by contiguous cytoplasmic bridges1-3. These muscle cells linked
together communicate when to contract and relax the heart through the pathway
of conduction. Conduction is the electrical signaling pathway through the heart
that produces normal cardiac rhythm (see Figure 1). This pathway is comprised
1

Figure 1. Normal electrical conduction through the heart. Conduction in the heart
begins with the sinoatrial (SA) node generating the electric signals that will
spread to the atrioventricular (AV) node resulting in ventricular depolarization
followed by repolarization in the reverse direction.
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of five elements: sino-atrial (SA) node, atrio-ventricular (AV) node, bundle of His,
left and right bundle branches, and Purkinje fibers. The SA node is the natural
pacemaker of the heart. It releases electrical stimuli at a regular rate that is
dictated by the needs of the body. Each stimulus passes through the myocardial
cells of the atria creating a wave of contraction which spreads rapidly through
both atria. This stimulus from the SA node reaches the AV node and is delayed
briefly so that the contracting atria have enough time to pump all the blood into
the ventricles. Once the atria are empty of blood the valves between the atria and
ventricles close. The electrical stimulus passes through the AV node and Bundle
of His into the Bundle branches and Purkinje fibers. This allows all the cells in
the ventricles to receive an electrical stimulus causing them to contract
(depolarize). Once the ventricles have contracted, the cells then relax,
repolarize, and are then ready for the next stimulus. Figure 2 displays an
electrocardiogram (ECG) that is a recording a heart rhythm.

The electrical stimulation moving through the heart is propagated by action
potentials. The action potential (AP) is the hallmark of electrical communication
used by the body and is the rapid transient depolarization and subsequent
repolarization produced by a concerted effort of many different ion channels (see
Figure 3). There are two types of APs in the heart: fast and slow. The slow
action potential consists of phases 0, 3, and 4, whereas the fast action potential
has phases 0, 1, 2, 3, and 4. In phase 0 of the fast AP, voltage-gated (Nav)
3

Figure 2. Normal ECG. An ECG is a recording of conduction across the chest. A
normal ECG illustrates that the heart is working correctly and allows for detection
of changes in how the heart beats. Figure adapted from
eleceng.dit.ie/tburke/biomed/ecg.png.
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Figure 3: Action potential waveforms in the heart. The top panel illustrates
examples of the variety of AP waveforms found in the heart. The different
currents involved in the fast AP are shown in the lower pane. Figure modified
from cvphysiology.com.
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channels open and cause the rapid depolarization of the membrane, due to
sodium (Na+) ions moving into the cell down their electrochemical gradient. Nav
channels then inactivate quickly while voltage-gated potassium (Kv) channels
activate to produce a transient outward current (Ito). This results in the small,
rapid repolarization seen in phase 1. The plateau phase (phase 2) consists of
voltage-gated calcium (Cav) channels activating producing an inward current that
is compensated with an outward potassium (K+) current (IKur). In phase 3, the
outward K+ current, IKr and IKs, starts to exceed the inward calcium current,
thereby repolarizing the cell back to its resting membrane potential. The diastolic
potential (phase 4) is accomplished by an outward K+ current equaling the action
of the Na+/K+-ATPase pump.

Normal heart rhythm occurs when the cardiac muscle cells, the conduction
pathway, and the voltage-gated ion channels all work properly and in sync with
one another. Any disruption can potentially cause dysfunction of the heart.

Arrhythmias and conduction dysfunction
Cardiac arrhythmias are considered a large collection of conditions where there
is abnormal electrical activity in the heart4,5. The heart may beat too fast or too
slow, and can be regular or irregular. Many arrhythmias are life-threatening and
can result in cardiac death2,6. Other arrhythmias may be less threatening and
symptoms may not present, but it may predispose an individual toward a stroke
6

or embolus. There are many types of arrhythmias from bradycardias,
tachycardias, automaticity, reentrant, and fibrillations (see Figure 4)7.
Bradycardia is a slowing of the heart beat that may be brought on by a slowed
signal from the SA node, a loss of activity from the SA node, or by blocking the
electrical signal from the atria to the ventricles (AV block). Tachycardia is an
increase in heart rate about 100 beats per minute. Tachycardia is not always
considered an arrhythmia. The sympathetic nervous system acts on the SA
node to increase heart rate in times of exercise or emotional stress. When
tachycardia results from extra abnormal impulses in the cardiac cycle, then it is
considered to be pro-arrhythmic. Automaticity refers to the potential a cardiac
muscle cell firing an action potential. All cardiac muscle cells have the ability to
initiate an AP, but normal conduction keeps the generation of APs to designated
cells, such as the SA node. When a cardiac muscle cell initiates an AP, it is
commonly called an ectopic focus. This has the potential of causing an extra
beat or seriously altering the contraction and proper flow of blood throughout the
body. An ectopic focus has the possibility of permanently modifying the
efficiency of the heart to pump blood. Reentrant, or re-entry, arrhythmias occur
when the electrical signal gets stuck in a small part of the heart and travels back
and forth in that area. The normal signaling pathway occurs through the whole
heart. This dysfunction may occur when a signal is delayed traveling to an area
in the heart. The heart cells have the potential of treating the delayed signal as a
new signal and will propagate this “new” signal while the old, or original, signal is
7

Figure 4: Dysfunctions in the heart. Alterations in ion channel activity can cause
multiple cardiac dysfunctions including Long QT syndrome, torsades de pointes,
and ventricular fibrillation. Figure modified from Keating 2001 7.
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still moving through the rest of the cardiac heart cells. This may lead to atrial
flutter and ventricular tachycardia. Fibrillation builds on the reentrant
phenomenon where the electrical impulse is stuck and in one area, except it is
now stuck in an entire chamber of the heart, i.e. atria or ventricle. The chamber
essentially flutters from the chaos of multiple signaling moving in every direction.
Although atrial fibrillation is not always considered life-threatening, ventricle
fibrillation (VF) is a medical emergency. VF is considered cardiac arrest since
the heart cannot pump blood when the ventricle cannot contract. This can lead
to death in a matter of minutes. Sudden Arrhythmia Death Syndrome (SADS) is
the term used to describe death in a person due to an arrhythmia. The most
common form of this is coronary artery disease that kills over 300,000 people
every year in the US.

Long QT, Short QT, Brugada’s
Disruption of the conduction in the heart can occur as a result of many reasons
from diseases (such as heart disease and diabetes), aging, smoking, excessive
drinking, inherited abnormalities, and alterations in cardiomyocyte action
potentials.

Cardiac action potential maladies can be caused by alterations in ion channel
function. Figure 4 displays one of these dysfunctions, Long QT Syndrome
(LQTS). LQTS is an extension of the QT segment as seen on an
9

electrocardiogram (ECG). The QT segment involves the depolarization and
subsequent repolarization of the ventricles in the heart. The QRS segment
shows the depolarization of the ventricle and the T segment illustrates the
repolarization of the ventricle. LQTS can be either inherited or acquired.
Acquired LQTS typically happens as a result of medications that alter ion channel
function. Inherited LQTS occurs when there is a mutation of a gene8-16.
Currently, there are twelve known inherited LQTS categories with LQT1, LQT2,
and LQT3 being the most common (see Figure 5). LQT1 and LQT2 make up
about 65% of all LQTS cases. LQT1 involves mutations the the KvLQT1
channel. KvLQT1 encodes IKs, one of two major repolarizing currents of the AP.
These mutations will delay repolarization of the action potential and increase
action potential duration (APD) leading to elongation of the QT segment.
Although LQT1 is the most common form of LQTS, it is the least severe. LQT2
occurs as a result of mutations in the hERG1 channel. HERG1 underlies IKr, the
other major repolarizing current of the cardiac AP. Altering the repolarization
phase, essentially delaying it, will extend the action potential and lengthen the
QT segment. IKr is the current responsible for ending the AP and normal function
of hERG1 could be considered protective against early after depolarizations
(EADs). LQT3 entails mutations in SCN5A, the channel that underlies the main
sodium current in phase 0 of the action potential. Extension of the depolarization
phase of the AP through mutations that cause a decrease in inactivation of the
Nav channel will also elongate the QT segment. Again, this has the potential of
10

Figure 5. Long QT disorder list. A list of known LQT disorders and the genes
associated with each disorder. Figure from eplabdigest.com.
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causing disruption to normal heart rhythm. Interestingly, Brugada Syndrome can
also be caused by mutations in SCN5A9. These mutations in SCN5A, that
underlies INa, cause a loss-of-function resulting in elevation of the ST segment
and dispersion of repolarization. This will cause a phase 2 reentry that has the
potential to trigger ventricular tachycardia. In addition to LQTS, another disease
that involves the QT segment is called Short QT Syndrome (SQTS). SQTS is the
result of a shortening of the QT segment typically resulting from an increase in
potassium current. The main repolarizing potassium currents are IKs and IKr17-19.
Increases in these currents can be the consequence of mutations of the channels
that underlie each current. Whether the QT segment is lengthened or shortened,
the result can be the same. Any alteration to the QT segment can alter the
cardiac AP and can lead to cardiac dysfunction15,16,18-20.

Alterations in IKr can cause arrhythmias
Alterations in IKr can lead to cardiac dysfunction8,11,15,18,20-26. If the current is
blocked, then an extension of the QT segment occurs and can result in LQT2. If
there is an increase in IKr, then a shortening of the QT segment transpires and
this may still lead to an arrhythmic event27.

HERG1A underlies IKr
Human ether-a-go-go-related gene 1 (hERG1) is the voltage-gated potassium
channel that underlies IKr19,28-31. IKr is one of two major potassium currents that
12

help repolarize the cardiac ventricular action potential (see Figure 6). Phase 3 is
considered the “rapid repolarization” phase where IKr is contributing nearly all of
the K+ efflux from the cell. This removal of potassium causes a rapid change in
the membrane potential from positive to negative potentials.

HERG1A activity during the ventricular AP
HERG1A has a unique functionality when it comes to the cardiac action
potential19,28-31. When the AP begins at phase 0, the membrane potential moves
very quickly from negative to positive potentials. Phase 0 happens in ~10 ms.
HERG1A is starting to transition from closed to open. However, hERG1A’s
inactivation rate is faster than its activation rate at positive potentials. By the time
phase 0 is complete and the membrane potential is around +40 mV, hERG1A
channels have mostly transitioned to the inactivated state. This allows for
hERG1A to be prepared for the final part of the plateau phase and the
repolarization phase. As the membrane potential starts to fall from positive
potentials, hERG1A transitions for inactive to the open state, starting the flow of
K+ efflux from the cell. As the potential becomes even more negative with K+
efflux, hERG1A channels recover even faster to their open state. This could be
considered a positive loop feedback. This large efflux of potassium from the cell
can be seen as the steep slope of phase 3 of the AP. Once the membrane
potential nears the resting potential, the channels transition to their closed state,
ready to start the next action potential.
13

Figure 6: HERG1A activity in the heart. HERG1A is in an inactivated state for
most of phase 0 and 1. During phase 2 repolarization, hERG1A transitions back
into its open state allowing a large efflux of potassium (phase 2 and 3). Figure
from Keating 20017.
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HERG1A characteristics
HERG1A is a voltage-gated potassium channel18,31. It consists of four subunits
coming together to create a pore-forming channel. Each subunit consists of six
trans-membrane domains or segments (S1-6) (see Figure 7). Segments 1-4 are
called the voltage-sensing domains with segment 4 (S4) having positive charges
every three amino acids. These charges sense a change in the membrane
potential and will move through the membrane outward allowing the channel to
open. Segments 5 and 6 are the pore-forming domains. The linker region that
connects segments 5 and 6 is called the pore-forming loop, or P-loop, and
shapes the pore region of the channel. Within the P-loop is a recognized amino
acid sequence that determines if it is a K+ channel. This sequence is GYG
(glycine - tyrosine - glycine). This sequence is thought to allow the K+ channel to
be selective towards K+ ions32. However, there are exceptions to this and
hERG1A is one of them. HERG1A’s sequence is GFG (glycine - phenylalaline glycine), but is still selective for K+ ions. Once hERG1A has four subunits
together to form a functional channel, it can then start to allow K+ ions to flow
through the pore region. This occurs by the channel transitioning from the closed
state to an open state. When the S4 segment senses a change in the membrane
potential, the segments (there is one on each subunit or four total) will move
outward causing a conformational change in the channel, opening the pore
region. K+ ions will start to flow out of the cell. Figure 8 shows typical gating
properties of hERG1A. In addition to opening and closing, hERG1A can also
15

Figure 7: HERG1A channel. The hERG1A channel consists of four subunits (one
is pictured). The red arrows point to the N-glycosylation consensus sequences
found on the P loop of hERG1A. Only the site N-terminal to the pore is
glycosylated. Figure from Sanguinetti 200631.

16

Figure 8: Gating properties of hERG1A. The above panel displays the unique
gating properties of hERG1A. Note that the rate of inactivation is faster as the
membrane potential becomes more positive, essentially transitioning past the
open state. At positive potentials, there is a decrease in hERG1A current
because most channels are in the inactivated state33.
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inactivate, but only through C-type inactivation. Channel inactivation can happen
one of two ways; C-type or N-type. N-type inactivation is also called the ball-andchain method where the N-terminus moves up and occludes the pore region to
stop the flow of ions. C-type inactivation is different. C-type inactivation happens
by a constricting of the pore-loop area of the channel, squeezing shut and thus
stopping the flow of ions. Most C-type inactivation is slow and doesn’t always
completely inactivate. However, C-type inactivation for hERG1A is fast and at
very positive potentials allows almost no potassium efflux31.

The hERG1A channel has been implicated in both inherited and drug-induced
arrhythmias4,7,14,19,22,23,27,28,34-58. Mutations are associated with ventricular
fibrillation, torsades de pointes (TdP), and arrhythmias. Drug-induced
arrhythmias can be triggered by occlusion of the pore region by certain drugs,
and/or by alterations in function of the channel by a mutation in hERG1A.

Over two hundred hERG1A mutations have been characterized that cause
disruption (reduction) of IKr and potentially cause long QT syndrome
(LQTS)8,11,15,18,20-26. The resulting LQTS can be caused through multiple
hERG1A dysfunctions. For example, mutations can lead to misfolding of the
protein causing retention in the endoplasmic reticulum (ER) where rapid
degradation will occur. Secondly, the mutation can produce dominant-negative
suppression or alter gating of the channel when there is co-assembly of mutant
18

and wild-type subunits. In either case, a loss-of-function occurs and a reduction
in IKr initiates the prolongation of phase II and III and an extension of the cardiac
action potential. The extension of the action potential can lead to early after
depolarizations (EADs) and arrhythmias. There is one known mutation in the
hERG1A channel that causes a shortening of the QT interval27. The shortening
is due to a gain-of-function by abolishment of inactivation. The repolarization
phase of the AP is more rapid and ventricular fibrillation and arrhythmias can
result from this “short QT syndrome”.

HERG1A is unique among voltage-gated potassium channels in that it can be
inhibited by many different types of drugs. HERG1A can be blocked by drugs
including antibiotics, antihistamines, antiarrhythmics, antipsychotics, and
antimicrobials, directly leading to induced arrhythmias. Because of the diversity
in structures among these drugs, establishing how and where hERG1A is
blocked has proven difficult. Drug-induced arrhythmias are widespread and
affect individuals of all age groups. Because prolonging the QT interval can lead
to TdP, arrhythmias, and even death, pharmaceutical companies screen all
potential drug candidates for hERG1A channel inhibition.

HERG1A N-glycosylation
HERG1A has two extracellular, N-linked glycosylation consensus sites located in
the S5-S6 linker region of the channel, very near the pore and selectivity filter.
19

The consensus sequence consists of NXS/T with N being Asparagine, X being
any amino acid except Proline, and S/T being a Serine or Threonine. Through
work completed by others and confirmed by our lab, the N-linked glycosylation
site at N629 is not glycosylated44,59,60. It is thought that the N629 site is too close
to the S6 segment and is not exposed to the glycosylation machinery to have
glycans attached. Thus, the functional hERG1A tetramer has the capacity for
four N-glycosylation structures to be attached within the pore region.

Known role of glycosylation on hERG1A
Most research completed about the glycosylation of hERG1A has focused mainly
on trafficking concerns for the channel. Originally, it was thought that N-linked
glycosylation was needed for proper trafficking of hERG1A to the surface of the
cell. A repeat of the study by Zhou showed that N-glycosylation is not needed for
correct trafficking to the surface, but removal of N-glycosylation altered the
stability of the channel in the membrane over the course of twenty four
hours8,44,59,60.

Glycosylation effects on other channels
Many voltage-gated ion channels are heavily glycosylated. All Nav and many Kv
channels are glycosylated, although in different locations on the channel and with
differing amounts and types of glycans. Several studies have suggested that
glycosylation, in particular, sialylation, may impact channel function 61-72. Gating
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of Nav1.4, Kv1.1, Kv1.2, and the Drosophila ShB channels are shifted to more
depolarized potentials with a reduction in N-glycosylation. In addition, data
suggest that rat neonatal and adult atrial and adult ventricular Nav channels are
more sialylated and therefore are more affected by changes in sialylation that
neonatal ventricular Nav channels.

Glycosylation pathway
Glycosylation is a post-translational modification. Glycosylation structures
attached to ion channels can make up more than 30% of a mature protein’s
mass. The addition and removal of glycans from proteins is completed by
glycosidases, glycosyltransferases, and transport proteins (see Figure 9). The
Consortium for Functional Glycomics recognizes more than 500 human genes
involved in glycosylation. With the human genome being composed of
approximately 30,000 genes, the genes required for the addition and removal of
glycans make up more than 1% of the entire genome66. Two forms of
glycosylation have been identified: N-linked and O-linked glycosylation. The
addition of glycosylation is not template-driven, but it is a highly ordered
process73,74. Each step in the pathway determines the next step.

N-glycosylation begins in the endoplasmic reticulum (ER). An oligosaccharide
precursor, composed of two core N-acetylglucosamines (GlcNAc) and five
mannose residues, is linked to a dolichol-phophate on the cytosolic side of the
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Figure 9: Glycosylation pathway. N-glycosylation is a regulated pathway in which
multiple proteins work collaboratively to add/remove sugars. The top panel
shows the initial steps in the pathway, and the bottom panel shows the complex
glycosylation that occurs in the Golgi. Figure from clemonslab.caltech.edu/nlinked.html.
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ER. The lipid-linked precursor is then flipped across the bilayer into the lumen of
the ER. The precursor is complete with the addition of mannose and glucose
structures. A protein complex, named oligosaccharyltransferase (OST), transfers
the dolichol precursor en bloc to an asparagine residue on a newly translated
protein. Following the covalent attachment of the precursor to the asparagines
residue, glucosidases remove all of the glucose residues. The glycoprotein
(newly glycosylated protein) is translocated to the cis-Golgi where the mannoses
are trimmed down leaving only three. Formation of complex glycans takes place
in the medial and trans-Golgi with sialic acid (SA) often being the terminal glycan
structure. Sialic acids are negatively charged at physiologic pH and can be
attached to other sialic acids. These sialic acids have the potential of
contributing to the negative surface charge of the protein.

Congenital disorders of glycosylation (CDG)
Currently, there are twenty-six forms of congenital disorders of glycosylation
(CDG) characterized75-78. Of these twenty-six forms, sixteen affect N-linked
glycosylation. CDG is a genetic disorder caused by glycosylation genes that are
missing or mutated. These defects can alter multiple steps in the glycosylation
pathway. CDG produces glycoproteins with decreased amounts and types of
glycans. Multiple systems within the body are influenced by CDG including
cardiovascular, muscular, and neuronal.
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Chagas’ disease
Chagas’ disease, also known as American trypanosomiasis, is a human parasite
disease that has no vaccine and no known cure79-83. The parasite, named
Trypanosoma cruzi, infects its host and releases a trans-sialidase to assist the
transfer of sialic acid residues from the host to the parasite. The host tissue
typically is the human heart, specifically cardiomyocytes. Sialic acid is a terminal
residue located on glycosylation structures. Many ion channels could be affected
by this alteration in glycosylation. Symptoms from this disease include
arrhythmias, myocarditis, cardiomyopathy, cardiac failure, and death.

Glycosylation is differentially expressed and remodeled in the heart
Cardiac glycogene expression is highly regulated66. This was determined by
measuring the relative expression of hundreds of glycogenes using GeneChip
microarray analysis of mRNA isolated from neonatal and adult atria and
ventricles. Microarray data were validated using real-time RT-PCR (qPCR)
analysis. The microarray and qPCR data were consistent. The data showed that
almost 50% of glycogenes tested were significantly differentially expressed
among the four myocyte types studied. Additionally, glycogene expression
between atria and ventricles at a single developmental stage and throughout
development of each chamber was also highly regulated. The result of the
removal of just one glycogene was enough to alter the conductance-voltage
relationship for Nav gating in atrial myocytes in mice.
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Subunit vs cell specific effects of glycosylation
N-glycosylation can affect cardiac action potential waveforms in one of two ways:
subunit or cell-specific. Altering N-glycosylation on a specific channel can modify
the AP. Furthermore, modulating the glycosylation machinery available in a
tissue can change the N-glycosylation of all channels in the tissue and still have
an effect on the AP.

Summary
It is well accepted that alterations to IKr that affect the action potential waveform
can lead to arrhythmias. Our previous work with sodium and potassium channels
showed that a change in sialylation modulates gating. In addition, certain
disorders, CDG and Chagas’ disease, display symptoms of cardiac unrest with a
change in glycosylation. The hERG1A channel is heavily glycosylated and
studies have shown glycosylation of hERG1A may be needed for proper stability
in the membrane. However, very little has been done to determine a specific role
or mechanism for N-glycans in hERG1A activity. Here, we describe in detail, a
role for N-glycans on hERG1A gating and kinetics. We find that N-glycans limit
hERG1A activity, thereby causing an extension of the cardiac AP.

In addition, we questioned the probable modulation, by N-glycosylation, of drug
inhibition of three well-prescribed antibiotics, Sulfamethoxazole (SMX),
Erythromycin, and Penicillin G. This study will provide insight into understanding
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the potential role of glycosylation for inherited, drug induced, and potentially
disease induced (eg. Chagas’ disease) arrhythmias. With arrhythmias claiming
the lives of hundreds of thousands of people every year and with millions of
people living with life-threatening arrhythmias daily, a greater awareness is
needed.
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CHAPTER 2
MATERIALS AND METHODS
Chinese hamster ovary cell culture and transfection
Pro5, Lec2, and Lec1 cells were grown in minimal media and transfected with
channel cDNA as previously described84,85. The cells were plated at ~50%
confluence onto 35 mm dishes 24 hours prior to transfection with a solution of 1
mL Opti-MEM (Invitrogen), 8 µL lipofectamine (Invitrogen), and 2.5 µg of channel
cDNA and incubated at 37 C in a 5% CO2 humidified incubator. 24 hours posttransfection, the transfection media was replaced with growth media, consisting
of alpha-minimum essential medium (αMEM; Invitrogen) with (Pro5 and Lec1)
and without (Lec2) ribo- and deoxyribonucleosides supplemented with 10% fetal
bovine serum (FBS; Hyclone), 100 U/mL penicillin, and 100 µg/mL streptomycin
(Mediatech). Cells were incubated at 37 C for another 48 hours prior to
electrophysiological recordings.

Vector construction and mutagenesis
The hERG1A cDNA in a pcDNA3 vector was a gift from Gail A. Robertson
(University of Wisconsin). Vector construction and mutagenesis were performed
similar to that previously described. The cDNA containing hERG1A open reading
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frame was inserted into either a pIRES2-DsRED2 vector or a pIRES2-EGFP
vector. The IRES2 vectors contain an internal ribosome entry site that allow both
the gene of interest and the DsRED2 or EGFP gene to be translated from a
single biscistronic mRNA.

Electrophysiology and data analysis
Whole cell recordings in CHO cells
The Pro5/Lec2/Lec1 expression system, cell lines of Chinese Hamster Ovary
cells, has been used successfully to determine the effects of glycosylation on
channel gating. The Pro5 cell line produces normal N-glycosylation and is the
parental cell line for both Lec2 and Lec1. The Lec2 cell line is deficient in the
CMP-sialic acid transporter and produces essentially non-sialylated proteins.
This cell line serves as a model for CDG type-IIf. The Lec1 cell line produces
proteins in a mannose-rich, or core N-glycosylated, state because of a deficiency
in the GlcNAc-T1 (N-acetylglucosaminyltransferase I) causing a disruption in
complex glycans being added to glycoproteins85.

Whole cell current recordings were performed using pulse protocols, solutions,
whole cell patch clamp techniques, and data analyses as previously described.
An Axon 200B patch-clamp amplifier in combination with a CV203BU headstage
(Axon Instruments) and a Nikon TE200 inverted microscope were used. Pulse
acquisition software (HEKA) operating on a Pentium III computer (Dell
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Computers) was utilized for pulse protocol generation. The ensuing analog
signals were digitized using an ITC-16 AD/DA converter (Instrutech). All
experiments were conducted at room temperature (~22 C). Drummond capillary
tubes were pulled into electrodes with a resistance of 1-2 M

using a model P-97

Sutter electrode puller. Series resistance was compensated 95-98%. The
extracellular solution was (mM): 65 NaCl, 5 KCl, 1MgCl2, 2 CaCl2, 155 sucrose, 5
glucose, 10 Hepes (pH 7.3). The intracellular solution used was (mM): 70 KCl,
65 KF, 5 NaCl, 1MgCl2, 10 EGTA, 5 glucose, 10 Hepes (pH 7.3). For the drugperfusion studies, the extracellular solution was identical to that listed above plus
the addition of each concentration of drug listed in Table 1. Immediately prior to
use, all solutions were filtered with a 0.2 µm Gelman filter. To ensure complete
dialysis of the intracellular solution, data was collected at least 5 minutes after
attaining whole cell configuration.

Conductance-voltage relationship for CHO cell recordings
Steady-state and kinetic gating parameters were examined through the use of
standard pulse protocols and solutions described by our lab and others. Cells
were held at -80 mV, stepped to more depolarized potentials (-80 mV to +50 mV
in 10 mV increments) for 4 seconds, then stepped back to -50 mV for another 4
seconds, and returned to the holding potential. Steady-state whole cell
conductance values (G) were determined by measuring the peak current (I) of
the tail current elicited at each test potential (Vp) and predicting a K+ Nernst
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Table 1. Concentrations for antibiotic drug study

Drug Name

Low

Mid

High

Concentration

Concentration

Concentration

Erythromycin

25 µg/mL

100 µg/mL

200 µg/mL

Penicillin G

10 µg/mL

50 µg/mL

200 µg/mL

Sulfamethaxozole

50 µg/mL

300 µg/mL

600 µg/mL

30

equilibrium potential (Ek = -84 mV) using Ohm’s law (G = I/(Vp - Ek)). The
maximum conductance generated by each cell was used to normalize the data
for each cell to its maximum conductance by fitting the data to a single
Boltzmann distribution (equation 1, solving for maximal conductance). These
single Boltzmann distributions were used to determine the average Va ± SEM and
Ka ± SEM values. The normalized data were averaged with those from the other
cells and the resulting average G-V curve was fit via least squares using the
Boltzmann relation below:
Fraction of maximal conductance = [1 + exp-((V-Va)/Ka)]-1

equation (1)

where V is the membrane potential, Va is the voltage of half-activation, and Ka is
the slope factor.

Steady-state inactivation
Cells were held at -80 mV before stepping to +20 mV for 3 seconds. Then we
stepped to -120 mV to +60 mV (in 10 mV increments) for 30 ms before stepping
back to +20 mV for 1 second and then returned to the resting potential. The
maximum current generated by each cell was used to normalize the data for
each cell to its maximum current by fitting the data to a single Boltzmann
distribution (equation 2, solving for maximal current), from which the mean V i ±
SEM

and Ki ± SEM values were determined.

Fraction of maximal current = yo + [1 + exp-((V-Vi)/Ki)]-1

equation (2)

where V is the membrane potential, Vi is the voltage of half-inactivation, Ki is the
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slope factor, and yo is the fraction of current that comes from constitutively active
channels.

Window Current
The product of the two Boltzmann distributions for steady-state activation and
inactivation. See formulas above.

Time constants for deactivation (Tn)
The deactivation protocol was set up to start at the membrane potential of -80
mV and then step to +20 mV for 1.6 seconds before stepping from -40 mV to 100 mV (in 10 mV increments) for 6 seconds each and then returning to the
resting potential. Deactivation time constants were determined by fitting the
current trace described above for each voltage tested. Whole current traces
were fitted using the Hodgkin-Huxley function of the PulseFit software suite
(HEKA). The current trace data were fitted to an exponential function.

Computer simulation of action potential
The Tentusscher-Noble-Noble-Panfilov model of human Endocardial ventricular
myocyte was implemented to simulate the AP under four experimental
conditions, namely Full glycosylation, Reduced sialylation, N-Glycanase treated,
and Mannose-Rich1. The extracellular concentration of K+, Na+, and Ca2+ are 5
mM, 140mM and 2mM respectively. The initial values of intracellular
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concentration of K+, Na+, and Ca2+ are 138.3 mM, 11.6 mM, and 0.0002 mM.
The rapid delayed rectifier current IKr is described by the following equation,
IKr

GKr K o /5.4 x r1 x r 2 (V

E K ) , where x is an activation gate and x is an
r1
r2

inactivation gate. √Ko/5.4 represents the Ko dependence of the current1. Based
upon the Va, Ka, Vi, Ki statistics from our voltage clamp experiments under four
HERG +/- sugars treatments, we computationally fit the model steady state
activation and inactivation curves.

Whole cell homogenization
Cells were rinsed with cold PBS and incubated for 5 minutes in ice cold sodium
pyrophosphate buffer with protease inhibitors (PI; 20 mmol/liter tetrasodium
pyrophosphate, 20 mmol/liter Na2PO4, 1 mmol/liter MgCl2, 0.5 mmol/liter
iodacetamide, 1.1 µmol/liter leupeptin, 0.7 µM pepstatin, 76.8 nM aprotinin). Cells
were then homogenized using manual tissue grinders. The homogenates were
centrifuged for 10 minutes at 1000 x g in a Beckman bench-top centrifuge. The
supernatant was centrifuged in an Eppendorf ultracentrifuge for one hour at
50,000 rpm after which, the pellet was resuspended in an appropriate volume of
sodium pyrophosphate buffer containing PIs. The lysates were then stored at 80 C and protein levels were determined using the Pierce BCA Protein Assay kit
and a Beckman DU 530 spectrophotometer.
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Cell surface biotinylation
Cell surface protein isolation (Pierce) was performed on hERG1A expressed in
Pro5, Lec2, and Lec1 cell lines. The cells were grown in T75 flasks until ~95%
confluent and then biotinylated for 30 minutes at 4 C. Then the reaction was
quenched, the cells harvested and lysed. Next, the biotinylated proteins were
isolated with NeutrAvidin™ Resin, rinsed, and then eluted with SDS-PAGE buffer
plus 50mM DTT. The protein sample at the end of the reaction is then run on a
SDS-PAGE gel (see below) and probed with hERG1A antibody to detect if the
hERG1A channel is found of the surface of the cell.

Immunoblots
Immunoblot gel shift analysis was performed as previously described 65,84,86,87.
Cell homogenates (1-3 µg/lane) were combined with one volume of 2x sample
buffer (12.5% upper Tris buffer, 10% glycerol, 5% 2-mercaptoethanol, and 3%
sodium dodecyl sulfate) and denatured in boiling water for 3 minutes. Samples
were then run on 5-7.5% SDS-PAGE gel for 90-110 minutes at 75-110 mV and
then transferred on nitrocellulose membranes using a semi-dry transfer cell
(BioRad). HERG1A was detected using a polyclonal primary antibody, HERG C20, raised in goat (Santa Cruz Biotechnology). After incubation with primary
antibody, the blot was treated with a Swine Anti-Goat conjugated to HRP
(Southern Biotech), secondary antibody, and visualized using an enhanced
chemiluminescence kit (Pierce). Deglycosylation of homogenates was
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performed through 2 hour treatments at 37 C with 5 mU of N-Glycanase /9 µg of
protein (PROzyme).

Data analysis and statistics
Data and statistical analyses were performed using Pulse/PulseFit (HEKA),
Sigma Plot (SSPS inc.), and Microsoft Excel. Student T-test, ANOVA, and Tukey
test were performed on the data produced by the electrophysiology recordings.
Significance was determined by p<0.05 where applicable.
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CHAPTER 3
N-GLYCANS LIMIT HERG1A ACTIVITY
Human ether-a-go-go-related gene 1 (hERG1), is the pore forming subunit of the
voltage-gated potassium channel whose activity is responsible for IKr, a key
component of late phase II and phase III of the human ventricular cardiac action
potential (AP) 17,18,88. A change in IKr can alter the repolarization phase of the AP
that can lead to modulated cardiac conduction. This altered conduction would be
reflected in an ECG by a change in the QT interval. HERG1 dysfunction is
responsible for Long QT2 disorders and a Short QT disorder16,19,89. Abnormal
hERG1 activity can lead to arrhythmias, torsades de pointes, cardiac disease,
and sudden cardiac death7,16,20,21.

The cardiac ventricular AP is comprised of 5 phases3. The rising phase, or phase
0, is produced by the rapid activation of voltage-gated Na+ channels that then
inactivate, shutting down the rapid depolarization. During this phase, hERG1A
channels are beginning to transition out of the closed state to either the open or
inactivated states. Phase 1 begins with a sharp, brief repolarization that occurs
due to a transient outward K+ current, Ito. The plateau, or phase 2, is produced
by combating K+ efflux and Ca++ influx such that the membrane potential remains
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almost constant. During phase 2 depolarization, hERG1A channels start to
recover from inactivation by transitioning to their open state. A positive feedback
loop begins as K+ leaves the cell, which will further repolarize the membrane and
lead to the opening of additional hERG1A channels that are recovering from
inactivation, thereby further repolarizing the membrane. Evidence for this positive
feedback mechanism is observed by the steep slope of Phase 3. Phase 4 is the
final recovery to the resting membrane potential before another AP begins.

HERG1A channels do not inactivate through fast N-type inactivation, but through
C-type mechanisms90. Typically, C-type inactivation is thought to involve pore
constriction and is slower than N-type inactivation. However, hERG1A
inactivation is fast and voltage-dependent and recovery from inactivation typically
occurs rapidly with the transition from the inactivated back into the open channel
state. This leads to increases in the rate of AP repolarization. Thus, any change
in hERG1A voltage-dependent gating and/or kinetics would lead to a change in
channel activity during the AP, and likely alter the rate of AP repolarization.

Ion channels are heavily glycosylated, with up to 30% of a mature protein’s mass
comprised of glycan structures69,91-94. Our lab and others describe how changes
in glycosylation and sialylation can affect gating and kinetics of voltage-gated Na+
and K+ channels65,68-71,87,93-97. The addition and removal of glycans from proteins
is completed by the activity of >200 glycosidases, glycosyltransferases, and
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transport proteins (glycogenes). In a recent report, we showed that the cardiac
glycome, defined as the complete set of glycan structures produced in the heart,
varies between atria and ventricles, and changes differentially during
development of each cardiac chamber98. Specifically, we showed that nearly half
of the 239 glycogenes tested were significantly differentially expressed among
neonatal and adult atrial and ventricular myocytes. The N-glycan structures
produced among cardiomyocyte types were markedly variable. We went on to
show that the regulated expression of a single glycogene was sufficient to
modulate AP waveforms and gating of less sialylated voltage-gated Na+ channels
consistently. These data provide initial insight into the possibility of a newly
described mechanism for controlling and modulating cardiac excitability through
regulated changes in cardiac glycosylation.

HERG1A has two extracellular, N-linked glycosylation consensus sites, N598
and N629, which are located in the S5-S6 linker region of the channel (or the
pore region) and very near the selectivity filter. Work done by others and
confirmed by our lab, showed that the N629 glycosylation site is not
glycosylated60. It is believed to be too close to the S6 domain and therefore not
exposed to glycosyltransferases as the newly synthesized channel moves
through the endoplasmic reticulum and Golgi. However, the N598 glycosylation
site is glycosylated. Here we question whether and how alterations in the types
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and amounts of N-glycans attached to hERG1A can modify channel gating and
kinetics.

Results
HERG1A is differently glycosylated
We questioned the impact of four variable glycosylation patterns on hERG1A
function. The Pro5, or parental cell line, is essentially fully glycosylated85. The
Lec2 cell line is deficient in a CMP-sialic acid transporter and produces
glycoproteins with essentially no sialic acid, and serves as a model for CDGIIf 7577,85

. The Lec1 cell line is deficient in GlcNAc-T1 (N-

acetylglucosaminyltransferase I) causing a disruption in the complex N-glycans
being added to glycoproteins85. As a result, a mannose-rich glycosylation
structure is produced. Exemplary N-glycan structures that are putatively
produced in each cell type are shown in Figure 10. The fourth glycosylation
pattern was achieved through enzymatic deglycosylation, using N-glycanase to
cleave the full N-glycan structure at the Asparagine residue. Our previous work
and work done by Thornhill’s group validate the use of this cell system and
enzymatic treatments to study channel function under variable levels of channel
glycosylation65,70,71,87,94-96.

To demonstrate that hERG1A is glycosylated differently and is expressed on the
cell surface under each condition of glycosylation, we performed immunoblot
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Figure 10. HERG1A is differently glycosylated. A: Immunoblot of hERG1a
expressing Pro5 cell lysates ± N-Glycanase treatment. Lane 1: Untreated
control. Lane 2: N-glycanase treated. B: Surface biotinylated lysates extracted
from Pro5 (Lane 1), Lec2 (Lane 2), and Lec1 (Lane 3) cells expressing hERG1A.
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analysis. As seen in Figure 10A, for hERG1A expressed in Pro5 cells, treatment
with N-glycanase causes a reduction in predicted molecular weight (MW), and a
less diffuse banding pattern, suggesting that N-glycanase completely removes
the N-glycan structure. Analysis of surface channel expression shows that
altered glycosylation does not affect channel trafficking of hERG1A in any of the
cell lines tested. The shifts in MW between Pro5, Lec2, and Lec1 suggest that
each cell line glycosylates hERG1A differently, and is expressed on the cell
surface. Further, note the heterogeneous banding pattern of the Pro5 and Lec2
lysates, and the more homogeneous pattern of the Lec1 and N-glycanasetreated lysates, indicating the variability of glycosylated hERG1A protein
expressed on the cell surface.

HERG1A function is modulated by N-glycans
hERG1A expressed in each cell line and following N-glycanase treatment
produced typical hERG1A currents as illustrated in Figure 11. Variable
glycosylation had no significant effect on the hERG1A current densities.
However, note the distinct characteristics of the current traces among the
differently N-glycosylated hERG1A channels. As an example for each condition
of reduced glycosylation, note the larger and faster (deactivating) tail currents at 50 mV following the four second test pulses. Details of the changes in hERG1A
biophysical characteristics are discussed below and summarized in Table 2.
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Figure 11. HERG1A current is altered by N-glycans. Whole cell current traces
for hERG1A expressed in Pro5, Lec2, Lec1, and N-Glycanase treated Pro5 cells.
Cells were stepped to increasingly depolarized potentials for 4 s from the -80 mV
holding potential, and then to -50 mV for 4 s to record the tail current.
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Table 2. Biophysical parameters for hERG1A as expressed in Pro5, Lec2,
Lec1, and following N-Glycanase treatment

hERG1A Channel

n

Full Glycosylation
11
(Pro5)
Reduced Sialylation
11
(Lec2)
Mannose-Rich
6
(Lec1)
N-Glycanse treated
3
Pro5

Va (mV)

Ka (mV)

Vi (mV)

Ki (mV)

-22.0 ± 1.3

8.4 ± 0.3

-74.4 ± 4.9

-19.0 ± 0.8

-13.7 ± 2.4*

8.6 ± 0.4

-56.2 ± 5.3*

-17.2 ± 1.3

-12.6 ± 2.4*

8.9 ± 0.4

-49.7 ± 5.1*

-15.4 ± 1.5*

-9.6 ± 2.2*

8.8 ± 0.4

-58.1 ± 7.7

-20.5 ± 0.6

Table 2. Data are the mean ± SEM. Va: Voltage of half-activation. Ka: Boltzmann
activation slope factor. Vi: Voltage of half-inactivation. Ki: Boltzmann inactivation
slope factor. * = significance (p<0.05).
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N-glycans promote hERG1A voltage-dependent activation
There is a consistent rightward shift in the current-voltage (I-V) relationships for
hERG1A under conditions of reduced glycosylation (see Figure 12). Note that
the full I-V curves were shifted by a depolarizing 5-10 mV along the voltage axis
for hERG1A expressed under conditions of reduced sialylation (Lec2), reduced
complex N-glycosylation (Lec1), and when fully deglycosylated (N-glycanase
treatment). These data indicate that N-glycans shift the activation voltage for
hERG1A to more hyperpolarized potentials.

The hERG1A steady state activation (SSA) relationships are shifted to more
depolarized potentials under conditions of reduced glycosylation
To determine more rigorously the impact of N-glycans on hERG1A activation, the
SSA relationships were determined using tail current analysis (Figures 11 and
12). There was a consistent, 8-12 mV depolarizing shift in the SSA relationships
for hERG1A expressed under each condition of reduced glycosylation (Figure 12,
Table 2). As Table 2 indicates, the voltages of half-activation (Va) measured
were also 8-12 mV more depolarized for less glycosylated hERG1A. The slope
factors of the SSA relationships, Ka, were unaffected. This suggests that Nglycans modulate hERG1A activation causing a linear shift in the SSA
relationship.
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Figure 12. HERG1A steady state activation curve is shifted to more
hyperpolarized potentials with full N-glycosylation. Current-voltage (I-V) and
steady state Activation curves for hERG1A expressed in Pro5 (square), Lec2
(circle), Lec1 (triangle) and N-Glycanase treated Pro5 (upside down triangle)
cells. Data are mean ± SEM. Top: IV curves. Lines are point-to-point. Bottom:
Steady state Activation (SSA) curves. Lines are fits of the data to single
Boltzmann distributions. Vertical, dotted lines project to the Va for each
condition. n= 11, 11, 6, 3 (See Table 2).
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N-glycans act to slow closing of hERG1A
Time constants for hERG1A deactivation were determined under each condition
of N-glycosylation. As observed in Figure 13, the deactivation time constants for
the fully glycosylated hERG1A are significantly greater than those observed for
the less glycosylated channels. This is most notable at less hyperpolarized
voltages, likely caused by the strong voltage-dependence of hERG1A
deactivation.

N-glycans cause a greater shift in voltage dependence of steady state channel
availability
To determine whether hERG1A channel availability is affected by N-glycans,
steady state channel inactivation (SSI) curves were measured (Figure 14, Table
2). Note the large, significant, depolarizing shift in steady state channel
availability under conditions of reduced glycosylation (21-30 mV). Specifically,
the voltage dependence of half-inactivation (Vi) for hERG1A under conditions of
reduced sialylation was 21 mV more depolarized than the fully glycosylated
hERG1A (Table 2). This depolarization of Vi was larger for hERG1A expressed
in a mannose-rich state (in Lec1 cells, ~ 30 mV), or following full deglycosylation
(~22 mV). The less glycosylated hERG1A channels inactivated at voltages
significantly more depolarized than the fully glycosylated control channels.
However, there was no significant difference in Vi measured among the less
glycosylated channels.
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Figure 13. N-glycans act to slow hERG1A closing. Top panel: HERG1A
deactivation time constants as expressed in Pro5 (squares), Lec2 (circle), Lec1
(triangle), and N-Glycanase treated Pro5 (upside down triangle) cells. Data are
the mean ± SEM deactivation time constant at a membrane potential. Lines are
point-to-point. Inset: Sample whole cell currents measured using the
deactivation protocol. Lower panel: Mean ± SEM deactivation times constants
at -50 mV for Pro5 (small slanted lines), Lec2 (mesh), Lec1 (large slanted lines),
and N-Glycanase treated Pro5 (horizontal lines) cells. n= 11, 11, 6, 3 (See Table
2). Significance (*) was determined by comparing Pro5 with each condition of
reduced glycosylation (p<0.05).
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Figure 14. Steady state channel availability is altered by N-glycans. Steady state
inactivation (SSI) curves for hERG1A expressed in Pro5 (square), Lec2 (circle),
Lec1 (triangle), and N-Glycanase treated Pro5 (upside down triangle) cells. Data
are mean ± SEM. Lines are fits of the data to single Boltzmann distributions. n=
11, 11, 6, 3 (See Table 1). Inset: Typical whole cell inactivating current traces
from a hERG1A expressing Pro5 cell.
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The large and variable shift in the voltage-dependence of activation and
inactivation causes a shift to more physiological potentials and an increase in
hERG1A window current
HERG1A activation, deactivation, and inactivation voltage dependence were
each modulated by changes in the glycosylation state of the channel. For each
gating mechanism studied, N-glycans caused a hyperpolarizing shift in the
voltage dependence of channel gating. However, the magnitude of the shift in
steady state activation and inactivation were not uniform; channel availability was
shifted about twice as much along the voltage axis as was channel activation.
The combined distribution of channels between the active and inactive states at a
membrane potential will affect the density of channels that are active at that
membrane potential. The area under the overlapping portions of the SSA and
SSI curves represents the window current, or the voltages at which hERG1
channels are active. Figure 15 plots the window currents measured under the
four conditions of glycosylation. The bell-shaped curves are the product of the
two Boltzmann relationships for steady state activation and inactivation, and
represent the predicted persistent channel activity (Fig. 15B). Because both the
activation and inactivation curves shifted to more depolarized potentials for less
glycosylated channels, the window current will also be shifted to more
depolarized potentials as observed. Note that the peak of the window current is
10-15 mV more depolarized for the less glycosylated hERG1A channels
compared to the fully glycosylated channels. In Figure 15C, the peak of each
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Figure 15. N-glycans limit hERG1A window currents with persistent hERG1A
activity at more hyperpolarized potentials. A: Overlapping SSA and SSI curves
for hERG1A as expressed in Pro5 (solid line), Lec2 (long dash line), Lec1 (short
dash line), and N-Glycanase treated Pro5 (dotted line) cells. Curves are the
Boltzmann fits from Fig. 12 and Fig. 14. B: Predicted window currents for
hERG1A. Lines are as described in panel A. C: Peak predicted normalized
window current. Bar graph comparing the relative magnitude (percent active
channels) of the peak window current for each condition.
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curve is greater for the less glycosylated channels, increasing by 1.6 fold for
Lec2, 2.4 fold for Lec1, and 1.4 fold for enzymatically deglycosylated cells. This
suggests an increase in window current with a reduction in N-glycans. Estimates
made to determine the area under the curve predict a 1.3-2.5 fold increase in the
amount of potassium moving across the membrane for the less glycosylated
hERG1A. To further examine the hERG1A channel persistent current, the
steady state currents following a four second pulse to voltages near the I-V peak
for the less glycosylated channels (0, 10, and 20 mV) showed a 23-80% increase
in window current compared to fully glycosylated controls (data not shown). With
reduced levels of N-glycosylation and sialylation, channels recovering from
inactivation during the AP would occur at smaller repolarizations and in greater
numbers, thus increasing the rate of AP repolarization. Simulation of the
ventricular AP predicted exactly this change in AP waveform (Fig. 16). That is,
simulation of the rightward shift and increase in hERG1A window current caused
increased phase II/phaseIII repolarization that would lead to reduced AP
duration. Thus, additional N-glycans, specifically, sialic acids, would act to limit
hERG1A activity during the AP causing an increased AP duration as discussed
later.
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Figure 16. in silico modeling predicts ventricular action potential is extended by
increased N-glycosylation. Predicted ventricular action potential waveforms,
assuming hERG1A activity as observed under each condition of glycosylation.
Computer simulation of the cardiac AP was done in collaboration with Dr. Hui
Yang, Department of Industrial & Management Systems Engineering, USF.
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Discussion
N-Glycans lead to a loss of hERG1A function
Here we show that N-glycans, particularly sialic acids attached to N-glycans, alter
gating and kinetics of hERG1A. Previous work on hERG1A and N-glycosylation
focused on trafficking and stability of the channel in the membrane 59,60. This
work represents the first set of data questioning the role of N-glycans on
hERG1A gating and kinetics. For all parameters studied, N-glycans shifted
voltage dependent gating to more negative potentials. The data show hERG1A
gating is modulated similarly under three different conditions of reduced
glycosylation ranging from a modest reduction of sialic acids to the complete
removal of N-glycans following N-glycanase treatment. The data show that
reduced N-glycosylation achieved through expression in Lec2 or Lec1 cells, or
through enzymatic deglycosylation, each altered channel activation and
inactivation similarly, with significant rightward shifts in steady-state activation,
steady-state inactivation, and deactivation kinetics observed for each condition of
reduced glycosylation. However, no significant differences in steady-state
activation or steady-state inactivation were observed among the three conditions
of reduced glycosylation. This suggests that the sialic acids attached to hERG1A
N-glycans are responsible for the majority of the effect of N-glycans on channel
function.
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While the direct effects of changes in channel glycosylation are similar to our
previous work on voltage-gated Na+ and K + channels, the impact on AP
waveform with such changes in glycosylation are novel – channel N-glycans limit
hERG1A activity, thereby acting to extend the cardiac AP. The rightward shifts
seen for both steady-state activation and inactivation under each condition of
reduced glycosylation would lead to a depolarizing shift in channel window
current (Fig. 15A). The larger rightward shift in the inactivation curve would also
cause an increase in the magnitude of the window current (Fig. 15B). For less
glycosylated hERG1A channels, a greater number of channels would be reactivated at depolarized potentials (less repolarized) compared to the fully
glycosylated channels. That is, the reduction in hERG1A glycosylation or
sialylation leads to a gain of hERG1A function. The positive feedback nature by
which hERG1A reactivates would lead to the rapid recovery of hERG1A, and
further increase K+ efflux at earlier times during the AP, and likely reduce AP
duration as observed through simulation of the ventricular AP (Fig. 16). As will
be discussed in detail below, as channel sialylation is regulated, or when it is
aberrant, hERG1A activity will change, thereby impacting AP repolarization.
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CHAPTER 4
PENCILLIN BLOCK OF HERG1A
HERG1A blockade by a range of drugs is linked to acquired long QT syndrome
(aLQTS)35,41,46,48-50,99. This results in an increased risk of sudden death from
ventricular arrhythmias. Several medications have been withdrawn from the
pharmaceutical market due to causing QT prolongation100,101. The successful
development of potential new drug therapies hinges on finding drugs that do not
induce cardiac arrhythmias. The most common problem in acquired long QT
syndrome is blocking hERG1A, delaying cardiac repolarization and increasing
the risk of torsades de pointes (TdP).

Previously, it was known that some medications that were used to treat cardiac
arrhythmias were also considered proarrhythmic. The Cardiac Arrhythmia
Suppression Trial (CAST) of 1991 investigated class I anti-arrhythmic agents that
blocked NaV channels and reduced conduction velocity of electrical impulses in
the ventricular myocardium. It became apparent that non-cardiac drugs,
including antibiotics, antipsychotics, antidepressants and antimalarials, can also
cause TdP. TdP is a twisting of the QRS complex around the isoelectric line of
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the body-surface electrocardiogram (ECG) and leads to an increased incidence
of sudden death.

Once it was known that non-cardiac drugs could block hERG1A and potentially
alter the cardiac AP, a flood of research went into understanding what can block
hERG1A and how to deduce new structures that would be anti-arrhythmic.
Understanding what current drugs on the market block hERG1A and at what
concentrations is essential to correctly prescribing medications to patients.

The discovery of penicillin is attributed to Scottish scientist and Nobel laureate
Alexander Fleming in 1928 (see Figure 17). This observation began the modern
era of antibiotics. Penicillin is a β-lactam antibiotic. It works by inhibiting the
formation of peptidoglycan cross-links in the bacterial cell wall.

The mechanism of action of penicillin at the molecular level starts with the
binding of penicillin to penicillin-binding proteins (PBPs) which are located in the
cell wall. Some PBPs are inhibitors of cell autolytic enzymes that literally eat the
cell wall and are most likely necessary during cell division. Other PBPs are
enzymes that are involved in the final step of cell wall synthesis called
transpeptidation. These enzymes are outside the cell membrane and link cell
wall components together by joining glycopeptide polymers together to form
peptidoglycan. The bacterial cell wall owes its strength to layers composed of
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Figure 17. Structure of Penicillin G. Molecular structure of Penicillin G. Formula
weight for Penicillin G is 334 g/mol. pKa is~3.

57

peptidoglycan. This is a complex polymer composed of alternating Nacetylglucosamine and N-acetylmuramic acid as a backbone from which a set of
identical tetrapeptide side chains branch, and a set of identical peptide crossbridges also branch. The tetrapeptide side chains and the cross-bridges vary
from species to species, but the backbone is the same in all bacterial species.
Each peptidoglycan layer of the cell wall is actually a giant polymer molecule
because all peptidoglycan chains are cross-linked. In gram-positive bacteria
there may be as many as 40 sheets of peptidoglycan, making up to 50% of the
cell wall material. In gram-negative bacteria, there are only one or two sheets
(about 5-10% of the cell wall material). Penicillin G has high activity against
gram-positive bacteria and low activity against gram-negative bacteria.

Penicillin acts by inhibiting peptidoglycan synthesis by blocking the final
transpeptidation step in the synthesis of peptidoglycan. It also removes the
inactivator of the inhibitor of autolytic enzymes, and the autolytic enzymes then
lyse the cell wall, and the bacterium ruptures. This latter is the final bacteriocidal
event.

Penicillin G was the first discovered penicillin in what is now a long list of
penicillins. It is absorbed orally with about 2/3 of the dose being degraded by
stomach acids. Penicillin G is very susceptible to beta lactamases, enzymes
which inactivate the compound by degrading the beta-lactam ring. All penicillins
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are acidic drugs that are acid labile and will degrade in neutral or basic solutions.
The degradation opens the beta-lactam ring and results in inactivation of the
penicillin. Penicillins are generally safe, having low toxicity, and can be used in
pregnancy and during lactation. Penicillin G is considered a short acting drug.
After oral administration, penicillin is absorbed mainly from the duodenum and
upper jejunum. The extent of absorption depends on the presence of food in the
gastrointestinal tract, gastric and intestinal pH and the relative acid-stability of the
penicillin derivative. Penicillin G is acid-labile and should be taken on an empty
stomach. Peak serum levels are reached within 30 to 60 minutes.

Penicillins are readily distributed into ascitic, synovial, pleural and pericardial
fluids. Distribution into tissues varies widely, with highest amounts in the kidney
and lower concentrations in the liver, lungs, skin, intestines and muscle. Small
amounts are found in all other body tissues and in the CSF. When the meninges
are inflamed, the CSF concentration is about 5% of the serum concentration and
can be therapeutic against sensitive organisms. Penicillins readily cross the
placenta and are distributed into breast milk. In patients with normal kidney
function, penicillin is excreted rapidly by filtration and active tubular secretion.
The elimination half-life is about 30 minutes.

HERG1A has been shown to be blocked by numerous antibiotics, including
erythromycin, sulfa drugs, and grepafloxacin. Grepafloxacin has been removed
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from the market due to QT prolongation and death. With all of the studies being
done on hERG1A drug block, no one has published any findings on the very first
antibiotic, Penicillin G. Here, we show that Penicillin G blocks hERG1A 102.

Results
To determine whether Penicillin G blocks hERG1A, hERG1A was expressed in
the fully glycosylated Pro5 cell line. Pro5 cells were exposed to three different
concentrations; 10 µg/mL, 50 µg/mL, and 200 µg/mL. Penicillin G was perfused
at 0.5 mL/min using the typical extracellular solution as the vehicle. Since
Penicillin G is readily absorbed, we did not need to add it to the intracellular
solution. Five minutes of equilibration time was allowed before recording. All
recordings were conducted while perfusing on solution.

HERG1A is blocked by Penicillin G
Initially, we were using Penicillin G as a potential negative control, since
extensive literature searches yielded no reports on Penicillin block of hERG1A.
What was found was that, at therapeutic concentrations, hERG1A function was
blocked by Penicillin G (see Figure 18). Maximal conductance of the 10, 50, and
200 µg/mL concentrations were normalized to the zero concentration. Figure 19
is a bar graph reflecting the % block at each concentration.
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Figure 18. Current trace at +20 mV for hERG1A at multiple drug concentrations.
Current trace showing block of hERG1A activity by Penicillin G at each
concentration tested (30 µM, 150 µM, and 600 µM).
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Figure 19. Percent block by Penicillin G. The total block by Penicillin G increases
with increasing concentrations of the drug. The high concentration of Penicillin G
shows a 35% block of hERG1A current.
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Discussion
For the first time, it was shown that Penicillin G blocks hERG1A function at
therapeutic concentrations. With more than 1/3 of hERG1A function blocked at
the 200 µg/mL concentration, the normal AP could be seriously compromised.
This blockade of hERG1A could potentially alter the cardiac action potential and
cause an acquired QT prolongation.

Although this is the first report that shows Penicillin G blocks hERG1A function,
we cannot overlook the fact that others have not shown any harmful side effects
of Penicillin G on cardiac function. There could be multiple reasons.

The first rationale is Penicillin G can be harmful when administered to patients.
Either no one has cited problems in the literature or these concerns have not
been attributed to hERG1A blockade. Although Penicillin G is a good antibiotic, it
does have its drawbacks. It is short acting and can easily be inactivated by
stomach acid. Normal administration of the drug is by injection. Even then,
Penicillin G is not used as readily as other antibiotics (many have an allergy to it).
As a result, there may not be enough data to confer whether there are dangerous
consequences to Penicillin G use.

The second point goes back to remodeling. The body has a wonderful way of
adapting to changes and unsafe environments. Penicillin G may block hERG1A,
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but that does not mean it will automatically cause QT prolongation. There are
multiple channels at work during the repolarization phase of the cardiac AP.
These additional sodium, calcium, and potassium channels may be up-regulated
or altered to balance out the blockade of hERG1A. Consequently, hERG1A may
be altered itself to change how a drug blocks it or how it works during the AP.

The third concern is that the harmful effects of hERG1A blockade are not seen
considering the half-life of Penicillin G is around thirty minutes. This may not be
adequate time for the drug to reach the heart and cause hERG1A dysfunction.
Additionally, it may reach the heart, but the thirty minute timeframe is not
sufficient to cause block of the channel. We show that direct application of the
drug to the outside of the cell for as little as five minutes is ample time to cause
block even with a low concentration of 10 µg/mL. However, cell expression
systems do not completely replicate events occurring in-vivo. They are merely
an excellent tool to begin looking at a question. Additional studies should be
conducted to properly comprehend the blockade of hERG1A by Penicillin G.

Any alterations in the cardiac action potential can be harmful. Penicillin G can
now be added to the long list of drugs that block hERG1A function. These
changes will likely have a detrimental effect on normal cardiac rhythm. This
could result in arrhythmias, TdP, and sudden cardiac death.
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CHAPTER 5
N-GLYCANS ALTER ANTIBIOTIC BLOCK OF HERG1A
In the last ~12 years, significant efforts were made to inform the world of
“Acquired LQTS Risk”. As a result, three important guidelines were released
named the Points to Consider document, ICH S7A and ICH S7B guidelines. The
Points to Consider document was released in 1997 by the Committee for
Proprietary Medicinal Products (CPMP). It stated facts about the assessment of
QT prolongation by non-cardiac medications. This was the beginning of global
understanding of potential dangers of new and current drugs that has forced
pharmaceutical companies to establish an improved cardiac safety profile. In
2000, the ICH S7A guideline was introduced by the International Conference of
Harmonization (ICH). The S7A guideline was titled, “SAFETY
PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS”. It is a
thirteen page document whose objective is to protect participants and patients of
clinical trials from potentially adverse effects of pharmaceuticals, while avoiding
unnecessary resources and animal use. The guideline goes on to dictate the
tests needed to be done for all of the physiological systems in the body. The ICH
S7B guideline called, “THE NON-CLINICAL EVALUATION OF THE POTENTIAL
FOR DELAYED VENTRICULAR REPOLARIZATION (QT INTERVAL
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PROLONGATION) BY HUMAN PHARMACEUTICALS”, was released by the ICH
in 2005. This guideline describes a non-clinical testing strategy for assessing the
potential of a test substance to delay ventricular repolarization (see Figure 20).
This guideline includes information concerning non-clinical assays and integrated
risk assessments. The ICH S7B expands upon the ICH S7A guideline. The
objective of the newest guideline is to identify whether a test substance has the
potential to delay ventricular repolarization and to correlate the extent of delayed
ventricular repolarization to the concentrations of the test substance. The results
can be used to reveal a mechanism of action and potentially estimate risk for
delayed ventricular repolarization and QT interval prolongation in humans. The
ICH S7B is a preclinical safety strategy that all pharmaceutical companies
comply with. The first step in this strategy is called the “golden standard” which
is an in vitro IKr assay to test for potential hERG interactions by means of patch
clamp studies. Taken as a whole, these documents assess and set forth steps
that pharmaceutical companies take to establish a safety profile regarding
cardiac events for all new drug candidates and already marketed drugs that have
been found to have adverse clinical events, a new patient population, or a new
route of administration raises concerns not previously addressed.

Hundreds of drugs have been found to directly affect the ventricular repolarizing
current, IKr, reduce K+ efflux, and lead to an arrhythmia35,54,55,103-105. This toxicity
is widespread, as indicated by analysis of a drug-monitoring database
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Figure 20. ICH S7B guideline. The ICH S7B guideline dictates strategies for
testing pharmaceutical drug candidates for possible arrhythmic events.
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maintained by the World Health Organization106-108. This is why the ICH S7B
guideline requires an in vitro assay on the main repolarizing current to test for
potential drug interactions. It has been found that 2-9% of patients taking
quinidine, an antiarrhythmic, produces TdP46. As a result, there have been
certain drugs taken off the market. From 1997 to 2000, three drugs were
removed from patient use. The first drug, Terfenadine, was in 1997. It is an
antihistamine formerly used for the treatment of allergic conditions. Terfenadine
is a prodrug, generally completely metabolized to the active form fexofenadine by
intestinal CYP3A4. Terfenadine itself, however, has a cardiotoxic effect and may
be absorbed and reach myocytes if the patient is concurrently taking a CYP3A4
inhibitor (e.g. erythromycin or grapefruit juice). In 1999, Grepafloxacin, an
antibiotic, was removed from the market due to increased QT prolongation. This
antibiotic is in a class of drugs called fluoroquinolones and fights bacteria in the
body. In 2000, Cisapride was withdrawn because of reports of causing Long QT
in patients. Cisapride is a parasympathomimetic which acts as a serotonin 5HT4 agonist. It is used for the symptomatic treatment of patients with nocturnal
heartburn due to gastroesophageal reflux disease. Cisapride was associated
with 270 adverse cardiac effects, specifically cardiac arrhythmias, and there have
been 70 fatal reactions.

To better understand how IKr is altered by drug block, we need to understand
how hERG1A is blocked by a drug. Figure 21 describes the potential
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Figure 21. Potential hERG1A block by antibiotics. Drugs can block hERG1A
several ways; 1) from the outside (in the case of SMX) and 2) from the inside,
interacting with the aromatic structures (as does Erythromycin). The mechanism
that Penicillin G uses to block hERG1A has not yet been elucidated.
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mechanisms to how a drug can block hERG1A. The most common areas are
either outside or inside the cell.

Blocking the flow of potassium through hERG1A from the outside of the cell is
not fully understood. Most work has been completed with divalent cations, since
so many reduce hERG current109-112. One thought is that the drug (divalent
cation) may physically occlude the pore region, essentially sitting in the opening
of the extracellular side of the channel. Since hERG1A is inactivated by C-type
inactivation, it is thought that the external side of the pore for hERG1A is larger
than other K+ channels.

Another externally oriented blocking mechanism may involve the acidic residues
on the S2 and S3 segments, specifically D226 and D456, along with the first four
arginine residues on S4. These residues work together during the activation and
deactivation of the channel through an electrostatic interaction. The divalent
cations may bind to or screen sites on the hERG1A channel altering the negative
electrostatic potential causing alterations to the gating and kinetics of hERG1A,
thereby modulating current. This mechanism is called a surface charge theory.

An additional theory is the voltage-dependent block theory where the drug
binding site is within the pore and the drug must cross part of the electric field of
the membrane to block hERG1A. Because the drug must cross the electric field
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the binding and unbinding is voltage-dependent. Drugs are not limited to utilizing
one of these theories, but can use a combination of any of the theories.

As for block from the intracellular side, it has been shown that hERG1A has
structural features that assist the binding of drugs better than other K+ channels.
HERG1A channels are blocked by drugs with diverse structures that cover
several drug classes, including antiarrhythmic, psychiatric, antimicrobial and
antihistamine48,110,113,114. Because of this unusual susceptibility to blockage by
drugs, it is thought that hERG1A has multiple unique binding sites. An Alascanning mutagenesis approach was used to identify residues of hERG1A that
interact with several drugs inside the pore region. Residues within the pore were
individually mutated and then evaluated for sensitivity to potent hERG1A
blockers50,115. Mutation of multiple residues (Thr 623, Ser 624, Val 625, Gly 648,
Tyr 652 and Phe 656) located in the S6 domain of the hERG1A subunit lowered
the affinity of multiple drugs, including MK-499, a potent anti-arrhythmic. The
same residues were found to be important for binding of cisapride, terfenadine
and several other drugs from different chemical classes55. Tyr 652 and Phe 656
have side chains that are essential for drug block. These aromatic residues are
turned toward the center of the channel only when the channel is open, which is
consistent with hERG1A being blocked after the channel has opened. It has
been reported that drugs block hERG1A in a state-dependent manner and most
have been shown to not block the channel in its closed state 116. Conceivably, the
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multiple aromatic side chains (eight per channel), will accommodate multiple
interactions by numerous drugs.

Reduction in or reduced IKr can lead to drug-induced arrhythmias. The drugs that
block hERG1A encompass almost every class of drugs on the market. These
drugs are known to elongate the repolarization phase, including many
antibiotics24,28,35,41,46,49,117-121. We chose to look at antibiotics for many reasons:
1) antibiotics are given to both men and women, 2) they are prescribed to
patients of all age groups from young to elderly, 3) antibiotics are provided to
individuals for many different diseases, and 4) hERG1A mutations can alter the
susceptibility of the channel complex to many drugs. The Sesti group
documented an increase in drug block of the hERG1/MiRP1 channel complex by
SMX when the complex was formed with a mutated MiRP1 subunit119,121. The T
to A mutation disrupts the NXS/T consensus site for N-linked glycosylation.
Although this mutation is not associated with inherited LQTS and it does not alter
the formation of the hERG1/MiRP1 complex, the polymorphism is implicated in
drug-induced arrhythmias.

To decide what antibiotics to investigate, we examined how a drug blocks the
channel. As described earlier, there are multiple ways to block hERG1A (see
Figure 21). Sulfamethoxazole (SMX) was selected since it may block hERG1A
extracellularly, apparently similarly to how many divalent cations block the
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hERG1A pore119. Erythromycin was chosen because it is believed to block the
hERG1A channel intracellularly and increasing concentrations of Erythromycin
cause a severe decrease in hERG1A current and an alteration in the voltage
dependence of channel block35,41. Penicillin G had not been shown to block the
hERG1A channel until our findings (summarized in chapter 4). However,
Ampicillin, an analog to Penicillin, was revealed to prolong the QT interval during
anaphylaxis to the prescribed antibiotic99. The cardiac abnormalities subsided
after a few days. We thought to use Penicillin G to test whether a drug that has
no known inhibition of hERG1A can become an inhibitor under conditions of
altered glycosylation. Our studies found Penicillin G does inhibit hERG1A
function and therefore cannot be used as a negative control.

Sulfamethoxazole (SMX) is a sulfonamide bacteriostatic antibiotic (see Figure
22). Its primary activity is against susceptible forms of Streptococcus,
Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, and oral
anaerobes. It is primarily used to treat urinary tract infections and can be used
as an alternative to amoxicillin-based antibiotics to treat sinusitis. Sulfonamides
are structural analogs and competitive antagonists of para-aminobenzoic acid
(PABA). They inhibit normal bacterial utilization of PABA for the synthesis of folic
acid, an important metabolite in DNA synthesis. Folic acid is not synthesized in
humans, but is instead a dietary requirement. This allows for the selective
toxicity to bacterial cells (or any cell dependent on synthesizing folic acid) over
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Figure 22. SMX block of hERG1A. The top panel displays the molecular
structure for SMX. The molecular weight is 290 g/mol and the pKa is ~5.7. The
bottom panel is a typical current trace at +20 mV showing a reduction in hERG1A
current at the following concentrations: 172 µM, 1 mM, and 2 mM.
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human cells. Bacterial resistance to SMX is caused by mutations in the folic acid
enzyme that inhibit PABA from binding and block folic acid synthesis.
Sulfamethoxazole is typically prescribed to adults and children, to treat
bronchitis, middle ear infections, and urinary tract infections. The dosage for an
adult (above 88 lbs.) is 800 mg every 12 hours, while the dosage for a child
(weighing less than 88 lbs.) is 9-13 mg per pound every 12 hours.

Eli Lilly’s research team isolated Erythromycin from the metabolic products of a
strain of Saccharopolyspora erythraea found in soil samples in 1949 (see Figure
23). Lilly filed for patent protection of the compound and U.S. patent 2,653,899
was granted in 1953. The product was launched commercially in 1952 under the
brand name Ilosone. Erythromycin was formerly also called Ilotycin.
Erythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar
to or slightly wider than that of penicillin, and is often used for people who have
an allergy to penicillins. For respiratory tract infections, it has better coverage of
atypical organisms, including mycoplasma and Legionellosis. Its structure
contains a 14-membered lactone ring with ten asymmetric centers and two
sugars (L-cladinose and D-desoamine), making it a compound very difficult to
produce via synthetic methods. The first synthetic form “A” was not accomplished
until the 80’s. Erythromycin inhibits the cytochrome P450 system which has the
potential of affecting the metabolism of many different drugs. If CYP3A4
substrates are taken with erythromycin, the levels of the substrates of these
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Figure 23. Erythromycin blocks hERG1A. The top panel displays the molecular
structure for Erythromycin. The molecular weight is 734 g/mol and pKa is ~8.8.
The bottom panel is a typical current trace at +20 mV showing a reduction in
hERG1A current at the following concentrations: 34µM, 136 µM, and 272 µM.
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drugs could increase often causing adverse effects. Erythromycin is easily
inactivated by gastric acid and is normally administered as an enteric-coated
tablet. It is very rapidly absorbed, and diffuses into most tissues and phagocytes.
Due to the high concentration in phagocytes, erythromycin is actively transported
to the site of infection where large concentrations of erythromycin can be
released. Erythromycin is typically prescribed to adults and children to treat strep
throat and Legionnaires disease. The dosage for an adult is 250-500 mg every
6-12 hours, while the dosage for a child is 3.4-5.6 mg per pound every 6 hours or
6.8-11.4 mg per pound every 12 hours. The typical serum levels range from 4-40
µM.

Penicillin is a group of antibiotics derived from Penicillium fungi (see Figure 24).
Penicillin antibiotics are historically significant because they are the first drugs
that were effective against many previously serious diseases such as syphilis
and Staphylococcus infections. Penicillins are still widely used today, though
many types of bacteria are now resistant. All penicillins are Beta-lactam
antibiotics and are used to treat bacterial infections. The term "penam" is used to
describe the core skeleton of a member of a penicillin antibiotic. This skeleton
has the molecular formula R-C9H11N2O4S, where R is a variable side chain.
Penicillin is typically prescribed to adults and children, to kill bacteria or prevent
bacterial growth. The dosage for an adult is 200,000-500,000 U (125-312 mg)
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Figure 24. Penicillin G blocks hERG1A. The top panel displays the molecular
structure for Penicillin G. The bottom panel is a typical current trace at +20 mV
showing a reduction in hERG1A current at the following concentrations: 30 µM,
150 µM, and 600 µM.
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every 4-6 hours, while the dosage for a child is 189-13,636 U per pound every 48 hours.

Our earlier work, summarized in chapter 3, demonstrated that N-glycans limit
hERG1A activity. We want to better understand how these alterations in Nglycans may impact antibiotic block of the channel. Utilizing the CHO cell
expression system of Pro5, Lec2, and Lec1 cells, we delivered different
concentrations of three antibiotics individually to the hERG1A channel to
determine whether and how changes in N-glycosylation modulate antibiotic block
of hERG1A. The data indicate that N-glycans play a protective role on hERG1A
antibiotic block122. Also, hERG1A block was never lessened by conditions of
reduced N-glycosylation.

Results
SMX block is altered by N-glycans
SMX is thought to block hERG1A extracellularly. A competitive inhibition study
done with SMX and cadmium showed that SMX blocks hERG1A in a similar
fashion to cadmium119. The hERG1A N-glycosylation structures reside in the P
loop. With the CHO cell expression system, we tested whether changes in Nglycans affected block of hERG1A. The data show decreases in N-glycosylation
caused an increase in hERG1A block (see Figure 25). If sialic acids are absent
from the N-glycan structure, an increase in maximum block is seen for the low
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Figure 25. Concentration dependent block by SMX. Top panel: Percent block of
hERG1A current by SMX at each concentration tested. Bottom Panel: Doseresponse curve of SMX. * is significant (p < 0.05).
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(50 µg/mL), mid (300 µg/mL) and high (600 µg/mL) concentrations. Interestingly,
when the complex N-glycosylation is absent, there is also a significant increase
in SMX block for every concentration tested. These data suggest that sialic acids
play a protective role on hERG1A block by SMX at saturating depolarizations.
The data also suggest that complex N-glycans may provide additional protection
against SMX block.

Erythromycin block is modified by complex N-glycans
Erythromycin has been a heavily researched drug relative to hERG1A block. It
has been linked to arrhythmias in individuals and shown to be pro-arrhythmic by
blocking hERG1A. The studies completed on Erythromycin conclude that the
aromatic residues on the S6 segment interact with the drug and block hERG1A
from the inside35,55,105. We questioned whether changes in N-glycosylation alters
Erythromycin block. The data indicate that alterations in N-glycans modify block
of hERG1A by Erythromycin (see Figure 26). For channels that are fully
glycosylated or missing sialic acids, a similar 10-15 % block was observed at 25
µg/mL. However, the Lec1 cells expressing hERG1A show a 20 % significant
block at the low concentration. As the Erythromycin concentration was
increased, no significant difference in block was observed among conditions.
This suggests that a saturating effect may occur. That is, regardless, of the Nglycans attached, Erythromycin will block hERG1A. This might not be surprising
since it is well established that Erythromycin blocks hERG1A from the inside.
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Figure 26. Concentration dependent block by Erythromycin. Top panel: Percent
block of hERG1A current by Erythromycin at each concentration tested. Bottom
Panel: Dose-response curve of Erythromycin. * is significant (p < 0.05).
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Perhaps, the impact of extracellular N-glycans on intracellular block is a minor
effect. Keep in mind that there was a small, but significant protective effect of Nglycans on Erythromycin block at the low concentration. If the N-glycans are in
the extracellular pore region, how do they protect against drug block from the
inside? There could be many possible explanations for this that include, 1) Nglycan structures can be rather large and the bulky structure may dip down
farther into the pore region affecting the surrounding area, and 2) hERG1A Nglycosylation may alter the channel structure within the plasma membrane. If the
channel structure is altered by reduced complex N-glycans, the aromatic
structures might be more or less accessible to drugs that will block hERG1A.

N-glycans alter Penicillin G block of hERG1A
In chapter 4, we showed that Penicillin G blocks the hERG1A channel in a
concentration dependent manner. Here, we asked whether alterations in Nglycosylation impact Penicillin G block at the following concentrations: 10 µg/mL,
50 µg/mL, and 200 µg/mL. A decrease in sialic acids significantly increase the
block by Penicillin G at every concentration tested (see Figure 27). The Lec1
cells expressing hERG1A show a greater block than control, but this does not
reach significance until the high concentration. These data suggest that sialic
acids account for alterations in Penicillin G block on hERG1A. Interestingly, at
the high concentration of Penicillin G, we see equal block between the Lec2 and
Lec1 suggesting that the sialic acids play a significant role in hERG1A block.
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Figure 27. Concentration dependent block by Penicillin G. Top panel: Percent
block of hERG1A current by Penicillin G at each concentration tested. Bottom
Panel: Dose-response curve of Penicillin G. * is significant (p < 0.05).
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Overall block by SMX, Erythromycin, and Penicillin G is different for each
antibiotic and N-glycans alter the block uniquely for each drug. This is the
measured overall blocking ability of hERG1A at maximized depolarizations.
However, achieving maximum depolarizations may not occur for all cells at
similar times during the AP and may not even be consistent among ventricular
myocytes. Thus, we sought to question whether there is an effect of N-glycans
on hERG1A block at less depolarizing potentials (less than maximum
depolarizations). In order to do this, drug block at -40, -30, -20, and -10 mV was
measured.

N-glycans modulate SMX block at small depolarizations
HERG1A block by SMX at each concentration is shown in figures 28-30. There
are several interesting, significant phenomenon that can be gleaned from this
data. When hERG1A is expressed in Lec2 cells, SMX block, at small
depolarizations, is greater than when the channel is fully glycosylated. The
increase in drug block was seen at every concentration of SMX. Note for the
Lec2 and Lec1 cell lines, there is no change in block with membrane potential.
This is quite different than that observed in the Pro5 cells. That is, apparently,
SMX blocks hERG1A in the absence of sialic acids and complex N-glycans in a
voltage-independent manner. For the Lec1 expressing hERG1A cells, an
increase in SMX block was also observed when compared to fully glycosylated
channels. These data suggest that sialic acids have the greater impact
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Figure 28. 50 µg/mL SMX block at small depolarizations. % block by SMX at
small depolarizations (-40, -30, -20, and -10 mV) for the 50 µg/mL concentration.
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Figure 29. 300 µg/mL SMX block at small depolarizations. % block by SMX at
small depolarizations (-40, -30, -20, and -10 mV) for the 300 µg/mL
concentration.
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Figure 30. 600 µg/mL SMX block at small depolarizations. % block by SMX at
small depolarizations (-40, -30, -20, and -10 mV) for the 600 µg/mL
concentration.
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on SMX block at small depolarizations than complex N-glycosylation. These
data suggest that the negative charges alter the mechanism of SMX block,
specifically its voltage-dependence.

Complex N-glycans impact Erythromycin block at small depolarizations
The previous data showed a small, but significant increase in overall
Erythromycin block of hERG1A at the low Eyrthromycin concentration, but only
for the Lec1 cells. However, no other significant effect of N-glycans on overall
Erythromycin block was observed. Interestingly, at small depolarizations (-40, 30, -20, and -10 mV), Lec1 cells expressing hERG1A show a large and
significant increase in Erythromycin block compared to Pro5 cells expressing
hERG1A. In fact, the Pro5 cells show no block from -40 to -20 mV (see Figures
31-33). Pro5 and Lec2 cells expressing hERG1A show the same voltagedependence, and still, the block by Erythromycin is greater in the Lec2 cells then
the Pro5 cells. These data are consistent with the removal of sialic acids is not
enough to alter voltage-dependent block of Erythromycin, but an increase in
block is still evident. In addition, the removal of complex glycosylation greatly
increase the Erythromycin block of hERG1A and may alter voltage dependent
block.
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Figure 31. 25 µg/mL Erythromycin block at small depolarizations. % block by
Erythromycin at small depolarizations (-40, -30, -20, and -10 mV) for the 25
µg/mL concentration.
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Figure 32. 100 µg/mL Erythromycin block at small depolarizations. % block by
Erythromycin at small depolarizations (-40, -30, -20, and -10 mV) for the 100
µg/mL concentration.
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Figure 33. 200 µg/mL Erythromycin block at small depolarizations. % block by
Erythromycin at small depolarizations (-40, -30, -20, and -10 mV) for the 200
µg/mL concentration.
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Sialic acid and complex N-glycans block Penicillin G at small depolarizations
Overall, hERG1A Penicillin block is greater when fewer N-glycans are present
(see Figures 34-36). At small depolarizations, fully glycosylated cells show no
block at -40 and -30 mV for every concentration of Penicillin G. The Lec2 cells
expressing hERG1A show a large and significant block by Penicillin at every
voltage (-40 to -10 mV) compared to the Pro5 expressing hERG1A cells.
Interestingly, the Lec1 cells show a Penicillin G block that shifts with
concentration. At the low concentration of drug, the Lec1 cells mimic the Pro5
cells with regard to voltage-dependence, even though the block is still greater in
the Lec1 cells. At the high concentration, the Lec1 cells mimic the Lec2 voltage
dependence and the block is not different between the Lec2 and Lec1 cells. The
sialic acids absent from hERG1A alter block (at small depolarizations) by
Penicillin G greater than any other N-glycan structure. The additional absence of
complex glycosylation was not effective in altering voltage-dependence more
than the sialic acids.

Discussion
Overall, N-glycosylation plays a protective role for hERG1A against antibiotic
block. The data show significantly less antibiotic block when N-glycans are
present. For all measurements tested (3 antibiotics at 3 concentrations each at
more than 5 different voltages and under two different conditions of reduced Nglycosylation), never was the block under conditions of reduced glycosylation
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Figure 34. 10 µg/mL Penicillin G block at small depolarizations. % block by
Penicillin G at small depolarizations (-40, -30, -20, and -10 mV) for the 10 µg/mL
concentration.
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Figure 35. 50 µg/mL Penicillin G block at small depolarizations. % block by
Penicillin G at small depolarizations (-40, -30, -20, and -10 mV) for the 50 µg/mL
concentration.
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Figure 36. 200 µg/mL Penicillin G block at small depolarizations. % block by
Penicillin G at small depolarizations (-40, -30, -20, and -10 mV) for the 200 µg/mL
concentration.
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significantly less than that observed under conditions of “full” N-glycosylation.
Interestingly, block at small depolarizations for SMX, Erythromycin, and Penicillin
are impacted by changes in glycosylation. N-glycans may alter the voltagedependence of block in different ways depending on the antibiotic. A lack of
sialic acids, and the negative charge associated with it, can render block to be
voltage-independent for SMX. This is consistent with the thought that SMX
blocks hERG1A from outside the cell (see Figure 37). The negative sialic acids
may have the ability to interact more with SMX since the N-glycans sit in the pore
region. The negative sialic acid residues on the terminal ends of the Nglycosylation structures may impact SMX block, since SMX is negatively charged
at physiologic pH, by altering the surface charge (or repelling the drug itself).
When sialic acid are absent from hERG1A, SMX may have the ability to more
readily bind to its site of action because this site is available.

Erythromycin block is apparently not affected by changes to the surface charge,
but may be affected by removal of complex N-glycans. Erythromycin has been
shown to interact with the aromatic structures deep in the pore region and
probably blocks hERG1A from inside the cell (Figure 38). This mechanism of
block may be too distant from the surface charges outside the channel to
observe an effect. Nevertheless, the complex N-glycans may potentially change
a structural element of hERG1A, thereby altering the affinity of a drug for its
binding site.
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Figure 37. Model of extracellular block on hERG1A
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Figure 38. Model of intracellular block on hERG1A
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Penicillin G block was altered with changes to glycosylation, and a concentrationdependent, voltage-dependence was seen for the Lec1 cells expressing
hERG1A. HERG1A expressed in the Lec2 cells showed an increase in block at
the small depolarizations. It is not known what mechanism Penicillin G uses to
block hERG1A. Based on the findings that Penicillin G block is altered by both
sialic acids and complex N-glycosylation, there is still an uncertainty as to how it
blocks hERG1A. However, at physiologic pH, Penicillin G is highly charged and
would not transverse the lipid bilayer suggesting that Penicillin G may only block
from the outside (Figure 37). The data suggest that sialic acid residues play the
biggest role in altering block by Penicillin G in these studies, possibly by repelling
or altering Penicillin G’s ability to interact with hERG1A because of the negative
charges on both Penicillin G and sialic acid. This implies that Penicillin G may
block hERG1A similarly to SMX utilizing the surface charge theory of block.

As discussed in chapter 3, alterations in glycosylation affect gating and kinetics
of hERG1A. These changes in N-glycan structures also alter antibiotic block of
the channel. Changes in hERG1A function (block) will alter IKr current. If there is
modification to a major repolarizing current of the cardiac AP, then the AP could
be compromised. The changing blocking characteristics of antibiotics on
hERG1A with alterations in N-glycans could become relevant in individuals with
pathologic changes in glycosylation. One example to illustrate the possible
impact of alterations in N-glycans is Chagas’ disease. A patient afflicted with
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Chagas’ disease typically presents with less sialylated cardiomyocytes meaning
a potential for a shortened QT interval. Given the data presented here, we might
predict that if a Chagas’ patient is given Penicillin G, there may be a greater
likelihood of drug block on hERG1A. This increase in block could lead to an
extension of the AP and may result in an adverse cardiac event. However, since
the Chagas’ patient may already have a short AP, then the Penicillin G might be
used therapeutically to correct the affliction instead of causing one. Our data
show that sialic acid impact cardiac function differently when investigating on
potassium channel’s function and drug block.

Multiple diseases affect glycosylation states in the body and are linked to
cardiovascular dysfunction. Understanding the probable role of N-glycosylation
on drug block will lead to safer drugs being put on the market.
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CHAPTER 6
FINAL DISCUSSION
Cardiac action potential waveforms are produced by the gating of multiple ion
channels. A change in ion channel function can lead to arrhythmias, torsades de
pointes, cardiac disease, and sudden cardiac death. HERG1A, one of these ion
channels, is partially responsible for the repolarization of the AP. Dysfunction of
hERG1A can result in multiple cardiac maladies and is the source of hundreds of
types of cardiac arrhythmias. Inherited, acquired, and drug induced arrhythmias
can all occur with alterations in hERG1A.

Physiologic and pathologic consequences
The impact of N-glycan dependent hERG1A activity on AP waveform is unique
among voltage-gated K+ channels
Here we show a depolarizing shift in hERG1A voltage-dependent gating
parameters with conditions of reduced glycosylation. We believe that sialic acid
play a large role in the micro environment surface charge surrounding many ion
channels. This surface charge directly affects normal function of the channels.
This molecular mechanism is consistent with some previous studies of Kv1 and
Kv4 channel isoforms (although not all), with conclusions made that reduced
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sialylation of the affected Kv1 and Kv4 isoforms limits Kv channel activity during
the AP (loss of function)65,87,93-95. The negative sialic acids likely impact the shift
in voltage-dependent gating through electrostatic mechanisms. In fact, for
several of these isoforms, only channel activation was affected by glycosylation.
For Kv1.2 channel inactivation was enhanced by decreased glycosylation. Both
of these mechanisms would lead to a further loss of channel activity during the
AP with reduced glycosylation71,72. Here we show that a less sialylated hERG1A
channel will be more active during the AP than a more heavily sialylated
hERG1A channel (see Figure 15). This gain of function with reduced
glycosylation, primarily sialylation, is unique among Kv channel isoforms.

Regulated changes in glycosylation could lead to modulated hERG1A activity
Changes in N-linked sugar types and levels, particularly sialic acids, alter
hERG1A function. Previously, we showed that the glycogenes whose products
are responsible for the addition and removal of glycans, are significantly
differentially expressed in the atria versus ventricles and during development of
each cardiac chamber66. Further, our data suggested that cardiomyocyte Nglycan structures are remodeled across the developing ventricle, particularly at
the level of complex N-glycans. We also showed that the major voltage-gated
cardiac Na+ channel, Nav1.5, is less sialylated in the neonatal ventricle than in
the adult ventricle, consistent with the regulated changes in cardiac ion channel
sialylation93. If hERG1A sialylation is similarly regulated throughout ventricle
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development, then, given our data shown here, we would predict that the more
sialylated adult hERG1A would be “less active” than the neonatal hERG1A
during the ventricular AP, leading to an increased AP duration in the adult, as
reported previously123,124.

Aberrant changes in glycosylation could lead to hERG1A dysfunction
It is well accepted that alterations in IKr often lead to aberrant cardiac AP
repolarization and arrhythmias. Currently, there are more than twenty-six known
forms of Congenital Disorders of Glycosylation (CDG) with a prevalence of 1 in
5000 births75-78. Of these, most affect N-linked glycosylation. CDG are genetic
disorders that onset because of missing or mutant glycogenes, primarily
glycosyltransferases. The mutant/missing glycogene results in proteins and
lipids with relatively modest reductions in glycosylation levels. The minimally
reduced levels of glycosylation grossly affect multiple systems including the
cardiovascular system, with many CDG patients presenting cardiomyopathy
and/or arrhythmias75-77. If hERG1A channels of CDG patients are less sialylated,
then one would predict decreased ventricular AP duration for those patients.

Chagas’ disease (Trypanasoma cruzi – T. cruzi infection) is a human parasite
disease that has no vaccine and no known cure and afflicts ~18 million people
wordlwide80,82,83. The mortality rate is ~30%, with nearly all terminal patients
experiencing heart failure preceded by ventricular tachycardia 81. T. cruzi
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releases a neuraminidase that cleaves sialic acids from the host tissue, which is
typically the heart. A recent study measured mouse ECG as a function of time
post-infection using two strains of T. cruzi to infect. The data indicated that ~60%
of infected mice (compared to ~5% of control) showed some conduction
abnormality125. If hERG1A is less sialylated in chagasic patients, then one would
predict increased hERG1A activity during the AP, and a decrease in AP duration
that could contribute to the ventricular arrhythmias experienced by many of these
patients. Taken as a whole, alterations in N-glycosylation will alter gating and
kinetics of hERG1A. This, in turn, may lead to alterations in the AP and
potentially adverse cardiac events. Recognizing that small changes to N-glycans
can have a large impact on the cardiac AP will facilitate understanding of many
cardiac diseases.

HERG1A antibiotic block is reduced with N-glycans
Here, we showed that N-glycans are protective for hERG1A against antibiotic
block. SMX, Erythromycin, and Penicillin G block were each greater with
reduced N-glycosylation, and block by each antibiotic was uniquely affected by
N-glycans. The data suggest that the negatively charged sialic acids seemed to
alter block by SMX more than Erythromycin suggesting that the sugars affect the
surface charge, and thereby alter the mechanism that SMX blocks the channel.
However, Erythromycin does not seem to be affected by surface charge changes
and its mechanism of block could be altered by sugars in a voltage dependent
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manner whereby the membrane potential is altered by the absence of sialic acid
on the extracellular surface causing an interior change to the binding site for
Erythromycin. Penicillin G was affected by both sialic acid and complex Nglycosylation suggesting that its mechanism of block may be through surface
charge effects, perhaps similarly to the effects of sialic acids on SMX block.

Antibiotic block may happen through multiple pathways
As discussed, one common theme of this report is that while N-glycans limit
hERG1A function, they also serve to protect hERG1A from antibiotic block. The
N-glycans may protect against antibiotic block of hERG1A through several
mechanisms. First, the findings from chapter 3 predict that N-glycans alter the
percentage of channels in a given state at a membrane potential and therefore
there should be a change in the percentage of block at a given voltage. That is,
we would predict that the rightward shift in voltage-dependent activation that
occurs with reduced glycosylation should cause a reduction in the percent block
at a membrane potential given that block occurs in a state other than closed.
However, this cannot be solely responsible for the variation in block with Nglycans reported here. In fact, because the data reported in chapter 5 are a ratio
of block comparing the current with drug to current without drug, the N-glycan
dependent modulation of gating on hERG1A is not measured. In addition, the
overall block would measure the ability of the drug to block all available channels
because the percent block is determined as a change in maximal conductance.
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Therefore, the data suggest an additional N-glycan effect on antibiotic block
beyond altering the state dependence of the channel at a given voltage.

A second possible mechanism by which N-glycans protect against antibiotic
block may involve structural changes in how hERG1A sits in the membrane or its
conformational state. If N-glycans alter how the channel is inserted into or how it
resides in the plasma membrane, then the affinity of a drug for its binding site
might be affected by the change in structure or conformation. Perhaps, even
access of the drug to its site of block may be altered. This could explain why
hERG1A expressed in Lec1 cells has an increase in block by Erythromycin. This
potential conformational change to the channel may alter the binding site of
Erythromycin giving the drug better access.

A third possible mechanism involves a more direct effect in which N-glycans form
a “shield” that limits drug interaction with the channel, almost like an umbrella
keeping the drug from its site of action. This shield could form a structural
hindrance or, perhaps as suggested by the Lec2 studies on SMX (and perhaps
Penicillin G), a charge effect. Altering the surface charge surrounding the
channel could directly affect the affinity of a drug for hERG1A. Further studies
need to be done to elucidate how N-glycans protect hERG1A from antibiotic
block.
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Future studies
The data show that N-glycosylation alters gating and kinetics of hERG1A such
that hERG1A function is limited by N-glycans. Also, the data demonstrate that Nglycans can protect hERG1A against antibiotic channel block. Both findings are
novel, potentially significant and likely occur through distinct mechanisms.
However, they represent only a start to our understanding of the full extent that
N-glycans impact hERG1A. Future questions to be addressed include, 1)
identifying how changes in block at small depolarizations (-40 to -10 mV range)
may affect the cardiac AP. Our findings indicate those voltages are relevant
during Phase III where hERG1A is most active in the AP. 2) determining the
mechanisms by which N-glycans affect block by antibiotics, focusing on hERG1A
block from either inside or outside of the cell and how N-glycans can alter both
mechanisms. Our data initially suggest that surface charge may play a role in
altering drug block of hERG1A when the drug blocks from the outside, and
complex N-glycans may modulate drug block from inside the pore region in a
structural manner. 3) expand computer simulation of the human ventricle to
include the effects of N-glycans on hERG1A function and block.

Summary
The hERG1A channel is essential to normal heart rhythm as hERG1A activity
underlies IKr. IKr is responsible for portions of phase II and phase III
repolarization of the cardiac AP. The data shown here indicate that hERG1A
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activity is limited by N-glycans attached to the channel, with channel sialic acids
responsible for most of the effect. This will effectively extend the ventricular AP.
As channel sialylation levels are altered, either physiologically or
pathophysiologically, hERG1A activity and AP repolarization will be modulated.
Physiological increases in channel sialylation would serve to further extend the
AP, while physiological and pathological reductions in channel sialylation would
lead to increased hERG1A activity and reduced AP durations. Either pathway
could increase susceptibility to ventricular arrhythmia. Thus, we have described
a novel mechanism by which hERG1A activity can be modulated by regulated
and aberrant changes in glycosylation, particularly sialylation. Such modulation
of hERG1A activity would affect the rate at which ventricular myocytes repolarize
during the AP and potentially increase susceptibility to ventricular arrhythmias.

Additionally, our findings show that N-glycans protect against antibiotic block of
hERG1A, likely through mechanisms distinct from the impact of sialic acids on
channel gating. HERG1A can be blocked by a drug from outside of inside the
cell. These mechanisms could be through surface charge, conformational
changes, and voltage dependent effects. Total block by each antibiotic was
affected differently by N-glycosylation. Additionally, voltage dependent antibiotic
block of hERG1A was modified by either sialic acids or complex N-glycans.
Acquired Long QT syndrome can affect anyone, even someone who has no
history of cardiac problems. Understanding how glycosylation is modulated in
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the heart, and how changes in glycosylation affect ion channel function may lead
to development of better anti-arrhythmic drugs with fewer side effects (such as
pro-arrhythmic behavior), prescribing the “right” medication, and even potentially
reversing an adverse cardiac event.
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